wan faiziah wan rahman

Dr. wan faiziah wan rahman

Universiti Sains Malaysia (USM)
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2021 in Medicina
Verified
Journal Article
Open access
PDF file
SDSylvia Annabel Dass
Sylvia Annabel Dass
KTKim Liu Tan
Kim Liu Tan
RRRehasri Selva Rajan
Rehasri Selva Rajan
NMNoor Fatmawati Mokhtar
Noor Fatmawati Mokhtar
EAElis Rosliza Mohd Adzmi
Elis Rosliza Mohd Adzmi
Venugopal BalakrishnanVenugopal Balakrishnan
Venugopal Balakrishnan
Triple-negative breast cancer (TNBC) is an aggressive breast type of cancer with no expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). It is a highly metastasized, heterogeneous disease that accounts for 10–15% of total breast cancer cases with a poor prognosis and high relapse rate within five years after treatment compared to non-TNBC cases. The diagnostic and subtyping of TNBC tumors are essential to determine the treatment alternatives and establish personalized, targeted medications for every TNBC individual. Currently, TNBC is diagnosed via a two-step procedure of imaging and immunohistochemistry (IHC), which are operator-dependent and potentially time-consuming. Therefore, there is a crucial need for the development of rapid and advanced technologies to enhance the diagnostic efficiency of TNBC. This review discusses the overview of breast cancer with emphasis on TNBC subtypes and the current diagnostic approaches of TNBC along with its challenges. Most importantly, we have presented several promising strategies that can be utilized as future TNBC diagnostic modalities and simultaneously enhance the efficacy of TNBC diagnostic.

3 June 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Ali MussaAli Mussa
Ali Mussa
RIRos Akmal Mohd Idris
Ros Akmal Mohd Idris
Naveed AhmedNaveed Ahmed
Naveed Ahmed
SASuhana Ahmad
Suhana Ahmad
Ahmad Hafiz MurtadhaAhmad Hafiz Murtadha
Ahmad Hafiz Murtadha
RHRosline Hassan
Rosline Hassan
In recent years, the idea that Vitamin C (Vit-C) could be utilized as a form of anti-cancer therapy has generated many contradictory arguments. Recent insights into the physiological characteristics of Vit-C, its pharmacokinetics, and results from preclinical reports, however, suggest that high-dose Vit-C could be effectively utilized in the management of various tumor types. Studies have shown that the pharmacological action of Vit-C can attack various processes that cancerous cells use for their growth and development. Here, we discuss the anti-cancer functions of Vit-C, but also the potential for the use of Vit-C as an epigenetic regulator and immunotherapy enhancer. We also provide a short overview of the current state of systems for scavenging reactive oxygen species (ROS), especially in the context of their influencing high-dose Vit-C toxicity for the inhibition of cancer growth. Even though the mechanisms of Vit-C action are promising, they need to be supported with robust randomized and controlled clinical trials. Moreover, upcoming studies should focus on how to define the most suitable cancer patient populations for high-dose Vit-C treatments and develop effective strategies that combine Vit-C with various concurrent cancer treatment regimens.

5 March 2021 in Genes
Verified
Journal Article
Open access
PDF file
Alaa SiddigAlaa Siddig
Alaa Siddig
TDTengku Ahmad Damitri Al-Astani Tengku Din
Tengku Ahmad Damitri Al-Astani Tengku Din
SNSiti Norasikin Mohd Nafi
Siti Norasikin Mohd Nafi
MYMaya Mazuwin Yahya
Maya Mazuwin Yahya
SSSarina Sulong
Sarina Sulong
wan faiziah wan rahmanwan faiziah wan rahman
wan faiziah wan rahman
Breast cancer commonly affects women of older age; however, in developing countries, up to 20% of breast cancer cases present in young women (younger than 40 years as defined by oncology literature). Breast cancer in young women is often defined to be aggressive in nature, usually of high histological grade at the time of diagnosis and negative for endocrine receptors with poor overall survival rate. Several researchers have attributed this aggressive nature to a hidden unique biology. However, findings in this aspect remain controversial. Thus, in this article, we aimed to review published work addressing somatic mutations, chromosome copy number variants, single nucleotide polymorphisms, differential gene expression, microRNAs and gene methylation profile of early-onset breast cancer, as well as its altered pathways resulting from those aberrations. Distinct biology behind early-onset of breast cancer was clear among estrogen receptor-positive and sporadic cases. However, further research is needed to determine and validate specific novel markers, which may help in customizing therapy for this group of patients.

1 December 2014 in European Journal of Integrative Medicine
Verified
Journal Article
Closed access
MHMohd Nizam Haron
Mohd Nizam Haron
wan faiziah wan rahmanwan faiziah wan rahman
wan faiziah wan rahman
SSSiti Amrah Sulaiman
Siti Amrah Sulaiman
Mahaneem MohamedMahaneem Mohamed
Mahaneem Mohamed

1 January 2019 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
NRNur Hidayati Mohamad Pakarul Razy
Nur Hidayati Mohamad Pakarul Razy
wan faiziah wan rahmanwan faiziah wan rahman
wan faiziah wan rahman
TWThin Thin Win
Thin Thin Win
Introduction: Vascular endothelial growth factor (VEGF) is an angiogenic factor that plays an important role inthyroid cancer. VEGF is known to have high affinity to VEGF receptors such as VEGFR-1 (Flt-1) and VEGFR-2 (KDR).Papillary thyroid carcinoma (PTC) is the most common thyroid cancer and studies showed the increasing incidence ofPTC arising in nodular hyperplasia. Targeted therapy on these growth factors and receptors are used in managementof both differentiated and undifferentiated thyroid carcinoma. This study aims to determine the expression of VEGFand VEGF receptors (VEGFR) in thyroid nodular hyperplasia and PTC. Methods: A cross-sectional study based onparaffinized archival tissue blocks of 113 nodular hyperplasias and 67 PTC from the thyroidectomy specimens inthe year of 2003 to 2014. The tissue sections were then stained by immunohistochemistry for VEGF, VEGFR-1 andVEGFR-2. The lymph node involvement and extrathyroid extension also were determined. Results: The mean age ofPTC patients was 44.7±15.8 years and nodular hyperplasia were 42.2±13.6 years. There was a statistical differenceof VEGFR-1 (p=0.028) and VEGFR-2 (p=0.003) expression between nodular hyperplasia and PTC. However, nosignificant difference of VEGF expression (p=0.576) between both diseases. Co-expression of VEGF and VEGFR-1was significant in both nodular hyperplasia (p=0.016) and PTC (p=0.03), meanwhile no relevant relationship for VEGFand VEGFR-2 expression (p>0.05). No significant association (p>0.05) between lymph node status and extrathyroidextension with age groups, gender, VEGF and VEGFR expression. Conclusions: VEGF, VEGFR-1 and VEGFR-2showed overexpression in both nodular hyperplasia and PTC. The expression of VEGFR-1 and VEGFR-2 are moresignificant in PTC with relevant co-expression of VEGF and VEGFR-1. Therefore, the inhibition of VEGFR offers apromising prospect for tumour management in thyroid carcinoma.

20 September 2021 in Genes
Verified
Journal Article
Open access
PDF file
WJWan Khairunnisa Wan Juhari
Wan Khairunnisa Wan Juhari
KNKhairul Bariah Ahmad Amin Noordin
Khairul Bariah Ahmad Amin Noordin
Andee Dzulkarnaen ZakariaAndee Dzulkarnaen Zakaria
Andee Dzulkarnaen Zakaria
wan faiziah wan rahmanwan faiziah wan rahman
wan faiziah wan rahman
WMWan Muhamad Mokhzani Wan Muhamad Mokhter
Wan Muhamad Mokhzani Wan Muhamad Mokhter
BZBin Alwi Zilfalil
Bin Alwi Zilfalil
Background: This study aimed to identify new genes associated with CRC in patients with normal mismatch repair (MMR) protein expression. Method: Whole-genome sequencing (WGS) was performed in seven early-age-onset Malay CRC patients. Potential germline genetic variants, including single-nucleotide variations and insertions and deletions (indels), were prioritized using functional and predictive algorithms. Results: An average of 3.2 million single-nucleotide variations (SNVs) and over 800 indels were identified. Three potential candidate variants in three genes—IFNE, PTCH2 and SEMA3D—which were predicted to affect protein function, were identified in three Malay CRC patients. In addition, 19 candidate genes—ANKDD1B, CENPM, CLDN5, MAGEB16, MAP3K14, MOB3C, MS4A12, MUC19, OR2L8, OR51Q1, OR51AR1, PDE4DIP, PKD1L3, PRIM2, PRM3, SEC22B, TPTE, USP29 and ZNF117—harbouring nonsense variants were prioritised. These genes are suggested to play a role in cancer predisposition and to be associated with cancer risk. Pathway enrichment analysis indicated significant enrichment in the olfactory signalling pathway. Conclusion: This study provides a new spectrum of insights into the potential genes, variants and pathways associated with CRC in Malay patients.